Evidence map›Paper›PMID 33765326›Full record

ArticleBJU international2021

Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer.

Catherine H Marshall, Jessa Tunacao, Varun Danda, Hua-Ling Tsai, John Barber, Rakhee Gawande, Clifford R Weiss, Samuel R Denmeade, Corinne Joshu

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJU international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Treatment of complex urethral stenosis in public centers from developing countries in 21st century.International braz j urol : official journal of the Brazilian Society of Urology
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Catherine H MarshallDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-2653-4110
Jessa TunacaoDepartment of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Varun DandaSidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
Hua-Ling TsaiDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
John BarberJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Rakhee GawandeDepartment of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Clifford R WeissDepartment of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Samuel R DenmeadeDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Corinne JoshuJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Johns Hopkins University · USThomas Jefferson University · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Bipolar Androgen Therapy for Progressive Castrate Resistant Prostate CancerR01CA184012 · NCI · JOHNS HOPKINS UNIVERSITY · PI DENMEADE, SAMUEL R · 2014 to 2018
$1.3M
NCI NIH HHS P30 CA006973NCI NIH HHS R01 CA184012NCI NIH HHS R01CA184012
6 · The paper itself

Abstract

objectiveTo investigate whether bipolar androgen therapy (BAT), involving rapid cyclic administration of high-dose testosterone, as a novel treatment for metastatic castration-resistant prostate cancer (mCRPC) promotes improvements in body composition and associated improvements in lipid profiles and quality of life. PATIENTS AND

methodsMen from two completed trials with computed tomography imaging at baseline and after three cycles of BAT were included. Cross-sectional areas of psoas muscle, visceral and subcutaneous fat were measured at the L3 vertebral level. Functional Assessment of Chronic Illness Therapy - Fatigue questionnaire and 36-item short-form health survey were used to assess quality of life.

resultsThe 60 included patients lost a mean (sd) of 7.8 (8.2)% of subcutaneous fat, 9.8 (18.2)% of visceral fat, and gained 12.2 (6.7)% muscle mass. Changes in subcutaneous and visceral fat were positively correlated with each other (Spearman's correlation coefficient 0.58, 95% confidence interval 0.35-0.71) independent of the effects of age, body mass index, and duration of androgen-deprivation therapy. Energy, physical function, and measures of limitations due to physical health were all significantly improved at 3 months. The improvements in body composition were not correlated with decreases in lipid levels or observed improvements in quality of life.

conclusionsIn the present study, BAT was associated with significant improvements in body composition, lipid parameters, and quality of life. This has promising implications for the long-term health of men with mCRPC.

Indexed as

AgedAged, 80 and overAndrogen AntagonistsAndrogensBody CompositionHumansLipid MetabolismMaleMiddle AgedProstatic Neoplasms, Castration-ResistantQuality of LifeTestosteroneAndrogen AntagonistsAndrogensTestosteroneandrogen-deprivation therapybipolar androgen therapybody compositioncancer survivorshipmetastatic castration-resistant prostate cancer#PCSMprostate cancer#ProstateCancer#uroonc

Identifiers

PMID33765326
PMCPMC9844547
OpenAlexW3137043250

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.